RxDoctor Payments Data

Ian Gilson, MD

Family Medicine · Foley, ALNPI 1225028855

Payments from drug & device makers

$9,070in general payments, 2019–2025

Across 597 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$944
  • Novo Nordisk$866
  • Boehringer Ingelheim$861
  • Lilly USA, LLC$819
  • Pfizer$784
  • AbbVie$734
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,070100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,070 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$88,804
Medicare patients
221
Services billed
5,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$40,330
RybelsusSemaglutide29$34,487
EliquisApixaban35$34,232
JardianceEmpagliflozin19$28,857
TrulicityDulaglutide11$25,059
MounjaroTirzepatide13$17,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,141
EntrestoSacubitril/Valsartan14$9,482
SymbicortBudesonide/Formoterol Fumarate13$3,024
Albuterol Sulfate HfaAlbuterol Sulfate103$2,632
Rosuvastatin Calcium210$1,945
Duloxetine Hcl47$1,747
Omeprazole132$1,627
Atorvastatin Calcium163$1,501
SynthroidLevothyroxine Sodium23$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$866$74,81759 claims
Lilly USA, LLCTrulicity, Mounjaro$819$42,90124 claims
PfizerEliquis$784$34,23235 claims
Boehringer IngelheimJardiance$861$28,85719 claims
GSKTrelegy Ellipta$205$12,14112 claims
NovartisEntresto$51$9,48214 claims
AstraZenecaSymbicort$944$3,02413 claims
AbbVieSynthroid$734$1,41823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →